News

Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.

A retrospective analysis of the DRIVE-FORWARD and DRIVE-AHEAD trials shows treatment-naive patients particularly fared well from the novel agent.

Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.

Despite being within the age group at highest risk for severe SARS-CoV-2 infection, a recent survey suggests that the population is not inherently more willing to socially isolate.

Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region.

A report released for AIDS 2020 warns the international AIDS response could be set back substantially by ongoing events.

CUSTOMIZE was designed to identify methods of implementing an experimental once-monthly, long-acting regimen antiretroviral therapy against HIV-1 into clinical practice.

How the inflammatory-based syndrome is affecting US children during the COVID-19 pandemic.

A discussion on how the pediatric inflammatory syndrome has begun to affect the US months into the pandemic.

Black Americans bear a disproportional burden and negative outcomes from the coronavirus.

Catch up with a review of our top drug pipeline stories from the past week.

. The following is a list of key recalls that may be relevant to infectious diseases, with links to full recall statements.

Hospitalized patients with unverified penicillin allergies may unnecessarily face greater risk of adverse drug events when given broader spectrum alternative antibiotics, according to a new study.

A discussion with a Yale expert on what new CDC data shows.

The indication is granted on the strength of clinical evidence showing 60% of treated patients achieved HIV RNA suppression at 96 weeks.

Judith Feinberg, MD, FIDSA, describes ongoing investigation into the immune response from COVID-19.

The purchase by Health and Human Services ensures US hospitals can secure the COVID-19 medication for the next few months.

How did the Western Pacific Region address rubella in recent outbreaks?

BNT162b1, a SARS-CoV-2 vaccine candidate, elicited promising early signs of immune activity in a placebo-controlled phase 1/2 study.

A brief overview of our top stories.

The European Commission has granted Marketing Authorization for a 2-dose Ebola vaccine regimen.

Jonathan Spero, MD, discusses workplace safety in the time of SARS-CoV-2.

Recent concerns have been raised about a spike protein mutation in SARS-CoV-2. Are these fears grounded?

Hollow-fiber infection model (HFIM) facilitates comparison of intermittent vs continuous infusion of ß-lactam antibiotic for K. pneumoniae

Despite guidelines discouraging use of anti-pseudomonal β-lactams and fluoroquinolones for community-acquired complicated intra-abdominal infection, about 75% of lower-risk patients are receiving such treatments, a new study found.

With more COVID-19 cases being realized in the US, the White House Coronavirus Task Force testified before the Senate today.

New recommendations are intended to aid biomedical firms in achieving licensure of a safe and effective vaccine.

Judith Feinberg, MD, FIDSA, describes surprising outcomes in many COVID-19 cases among people living with HIV.

Insurance data shows family members in the same household could also become infected.

In a recent CDC Morbidity and Mortality Weekly Report, data showed greater intensive care unit admission and mechanical ventilation for this group of patients.